Psoriatic Arthritis Treatment Market - Global Market Share, Trends, Analysis and Forecast 2023 - 2032

The global psoriatic arthritis treatment market size was estimated to be US$ 7.15 billion in 2020 and is expected to reach US$ 15.75 billion by 2031 at a CAGR of 7.5%.

Psoriasis is a persistent inflammatory skin condition associated to joints on account of PsA’s. Psoriasis arthritis might be misdiagnosed as rheumatoid arthritis or gout.

Psoriasis arthritis is recognized by irritation of joints and inflammation, especially in the area where the tendons or ligaments are associated with the bone. The irritation of entheses is named as Enthesitis and can be seen at the lower part of feet, Achilles ligaments, pelvis, ribs, and spine. On the off chance, when left untreated, enthesitis may result into calcification or fibrosis of tissues. Psoriasis arthritis in the spine is known as psoriasis spondylitis which might cause swelling and firmness in body part, for example, lower back, spinal vertebrae, pelvic, neck, and others. Spondylitis can cause aggravation in tendons and joints of arms, hips, feet, legs, and others. Psoriasis arthritis may likewise cause inflammation along with swelling of fingers and toe in a demented manner. This agitative condition is named as Dactylitis.

Nonetheless, increased customer awareness, supported by different missions coordinated by private and public associations, is probably going to decrease the paces of misdiagnosis or erroneous treatment. Moreover, the significant expense of treatment, and the negative impacts of certain drugs are relied upon to control market development in coming years. Increasing commonness of psoriasis arthritis, which as explained above is an immune system issue brought about by an attack of the body's immunity on joints and skin, is ready to drive the demand for psoriasis arthritis drugs treatment marketplace in coming years ahead.

The sickness is more observed among the patients previously suffering from plaque psoriasis. According to a review published by Celgene Corporation, about thirty percent of the patients with psoriasis suffer an inflammatory condition involving joints, known as psoriasis arthritis.

The significant expense and unfavorable impacts of drugs utilized in the treatment of psoriasis arthritis are the factors that are relied upon to hinder the development of the worldwide psoriasis arthritis treatment market during the projection period.

NSAIDs are probably going to lose portions of the overall industry because of the accessibility of various choices with further developed health and practicality profiles and better outcomes. DMARDs are projected to maintain their essence because of their first-line of treatment, demand, and pertinence of corticosteroids, and the forthcoming dispatches of key pipeline items, for example, upadacitinib, filgotinib, and BMS-986165.

The Coronavirus pandemic negligibly affected the PsA treatment market. The telehealth management and medical care being offered by the healthcare institutions are proving valuable to help the PsA patients regardless of the inaccessibility of the dermatologists in the midst of lockdown circumstance worldwide. As far as distribution channel is considered, the market for psoriasis arthritis treatment is segmented into emergency clinic drug stores, retail drug stores, online drug stores, and others. The clinic drug stores segment is projected to arise dominant during the speculation period of 2021-2031. Most noteworthy preferences given to the medical clinics for the administration of basic conditions, increasing utilization of fundamental treatments, and accessibility of expert healthcare suppliers are factors contributing to the most elevated growth to these facilities since 2020.

In any case, the online drug stores segment is probably going to boom at the most elevated CAGR owing to increasing utilization of internet across the globe, comfort of online shopping, and numerous advantages offered by online drug store in the province they operate.

North America and Europe, all in all, added to the greater part of the general income in 2018-2019. The pattern of biosimilars in emerging business sectors like China, India, and South Korea, is a critical propeller for development. What's more, the generally speaking financial turn of events, improvement in healthcare infrastructure, increase in extra cash, and lift in customer awareness are probably going to add to the regional development rate of the marketplace during 2021-2031.

Psoriatic Arthritis Treatment Market Value Share Analysis, by Geography (2022)

The report titled “Psoriatic Arthritis Treatment Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032”, wherein 2021 is the historic period, 2022 is the base year, and 2023 to 2032 is the forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the Psoriatic Arthritis Treatment Market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market.

The Psoriatic Arthritis Treatment market is segmented as drug class, product type, route of administration, and region. Based on drug class, the Psoriatic Arthritis treatment market is segmented into NSAIDs, DMARD, Biologics, Others. Based on product type, the Psoriatic Arthritis treatment market is segmented into Prescriptions, OTC, other. Based on route of administration, the Psoriatic Arthritis treatment market is segmented into Topical, Oral, Injectable, other. Based on geography, the Psoriatic Arthritis Treatment Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America is sub-segmented into the United States, Canada and Rest of North America. Europe is sub-segmented into Germany, United Kingdom, Italy, France, Spain, and Rest of Europe. Asia Pacific is sub-segmented into China, Japan, India, Australia, and Rest of Asia Pacific. Middle East & Africa is sub-segmented into Saudi Arabia, UAE, South Africa and Rest of Middle East & Africa. South America is sub-segmented into Brazil and Rest of South America.

The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment and would identify the segment of the company focusing on Psoriatic Arthritis Treatment Market. Further, market share of prominent companies in the Psoriatic Arthritis Treatment Market would also be estimated.

The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, swot analysis, and research and development focus of all the Psoriatic Arthritis drug companies. The Psoriatic Arthritis Treatment Market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution. Product portfolio would focus on all the products under the Psoriatic Arthritis treatment business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the Psoriatic Arthritis Treatment Market.

The key players of the Psoriatic Arthritis Treatment Market are AbbVie Inc., Johnson & Johnson Services, Inc., Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Bausch Health Companies Inc., Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer, Inc., and UCB S.A, and others.

Psoriatic Arthritis Treatment Market Key Segments:

Based on drug class type

• NSAIDs
• DMARD
• Biologics
• Others

Based on product type

• Prescriptions
• OTC
• Others

Based on route of administration

• Topical
• Oral
• Injectable
• Others

By Region

• North America
  • United States
  • Canada
  • Rest of North America
• Europe
  • Germany
  • United Kingdom
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  
  • Japan
  • India
  • China
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Middle East & Africa
  •  UAE
  • Saudi Arabia
  • South Africa
  • Rest of the Middle East & Africa
• South America
  • Brazil
  • Rest of South America